GW Pharma's cannabis-based epilepsy drug cuts seizure rates by 50%
- GW Pharma's Epidiolex is an oral drug made from cannabidiol, a non-psychoactive part of the marijuana plant.
- In an open-label study of patients with severe, treatment-resistant epilepsy, Epidiolex reduced the number of seizures by an average of 54%, FierceBiotech reports.
- The study included a total of 213 people, ranging from toddlers to adults. The adverse event rate was tolerable for the most part, with only 6% of patients dropping out because of adverse events.
GW's proprietary cannabinoid development platform has been the basis for successful pipeline development so far. The most recent study results included very positive data on a subset of patients with Dravet syndrome, who had a 53% decrease in seizures during the 12-week study, as well as patients with Lennox-Gastaut syndrome, who had a 55% decrease in seizures during the trial.
Currently, GW is planning phase III trials for both disorders, and is also enjoying the benefits of being enrolled in the FDA's fast-track program. In addition, GW has partnered with Sativex to distribute its EU-approved drug for the treatment of muscle spasms in patients with multiple sclerosis.